Form 4: Vertex Pharmaceuticals EVP, Chief Scientific Officer David Altshuler Reports Stock Transactions

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the disposition of shares under a pre-arranged trading plan.

Summary

• David Altshuler, EVP, Chief Scientific Officer of Vertex Pharmaceuticals, filed a Form 4.
• On February 26, 2025, 5,954 shares of Common Stock were disposed of at a price of $479.61.
• On February 27, 2025, 1,272 shares of Common Stock were sold at a price of $480.
• Following these transactions, Altshuler beneficially owns 32,974 shares of Vertex Pharmaceuticals.
• The transactions were made pursuant to a company-approved trading plan under Rule 10b5-1, entered into on August 8, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports stock transactions under a pre-existing trading plan, with no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.

Key Dates